Journal of Biological Chemistry · 2006 · 48 citations · 24 references
Life SciencesBiochemistryMolecular BiologyEnzyme MechanismEnzymologyStructural BiologyCatalytic MechanismsEnzyme Active SitesEnzyme FunctionEnzyme InhibitionEnzyme KineticsEnzyme-substrate RecognitionActive Site CharacterizationCatalytic Site ArchitectureCysteine CatalysisCysteine MetabolismCysteine OxidationMetal-binding PropertiesNon-heme Iron EnzymesSubstrate Binding Specificity
The first major step of cysteine catabolism, the oxidation of cysteine to cysteine sulfinic acid, is catalyzed by cysteine dioxygenase (CDO). In the present work, we utilize recombinant rat liver CDO and cysteine derivatives to elucidate structural parameters involved in substrate recognition and x-ray absorption spectroscopy to probe the interaction of the active site iron center with cysteine. Kinetic studies using cysteine structural analogs show that most are inhibitors and that a terminal functional group bearing a negative charge (e.g. a carboxylate) is required for binding. The substrate-binding site has no stringent restrictions with respect to the size of the amino acid. Lack of the amino or carboxyl groups at the α-carbon does not prevent the molecules from interacting with the active site. In fact, cysteamine is shown to be a potent activator of the enzyme without being a substrate. CDO was also rendered inactive upon complexation with the metal-binding inhibitors azide and cyanide. Unlike many non-heme iron dioxygenases that employ α-keto acids as cofactors, CDO was shown to be the only dioxygenase known to be inhibited by α-ketoglutarate. The first major step of cysteine catabolism, the oxidation of cysteine to cysteine sulfinic acid, is catalyzed by cysteine dioxygenase (CDO). In the present work, we utilize recombinant rat liver CDO and cysteine derivatives to elucidate structural parameters involved in substrate recognition and x-ray absorption spectroscopy to probe the interaction of the active site iron center with cysteine. Kinetic studies using cysteine structural analogs show that most are inhibitors and that a terminal functional group bearing a negative charge (e.g. a carboxylate) is required for binding. The substrate-binding site has no stringent restrictions with respect to the size of the amino acid. Lack of the amino or carboxyl groups at the α-carbon does not prevent the molecules from interacting with the active site. In fact, cysteamine is shown to be a potent activator of the enzyme without being a substrate. CDO was also rendered inactive upon complexation with the metal-binding inhibitors azide and cyanide. Unlike many non-heme iron dioxygenases that employ α-keto acids as cofactors, CDO was shown to be the only dioxygenase known to be inhibited by α-ketoglutarate. The first major step in cysteine catabolism involves its conversion to cysteine sulfinic acid by cysteine dioxygenase (CDO), 2The abbreviations used are: CDO, cysteine dioxygenase; XAS, x-ray absorption spectroscopy; EXFAS, extended x-ray absorption fine structure; ES, enzyme-substrate. which is a nonheme iron-containing dioxygenase present in mammalian tissues. CDO plays an important role in the formation of essential metabolites such as taurine and sulfate. Because cysteine is toxic at high levels (1Weinstein C.L. Haschemeyer R.H. Griffith O.W. J. Biol. Chem. 1988; 263: 16568-16579Abstract Full Text PDF PubMed Google Scholar), CDO assists in maintaining low intracellular cysteine levels without compromising its availability for incorporation into proteins and synthesis of major metabolites. Since the early studies on CDO by Sörbo and Ewetz (2Sörbo B. Ewetz L. Biochem. Biophys. Res. Commun. 1965; 18: 359-363Crossref PubMed Scopus (49) Google Scholar), there have been great advances in understanding the regulation and biochemical properties of this enzyme. However, there is little information regarding the active site of CDO and its specificity for the only known substrate, l-cysteine (3Ewetz L. Sörbo B. Biochim. Biophys. Acta. 1966; 128: 296-305Crossref PubMed Scopus (59) Google Scholar). Herein we report the results of probing the active site requirements of CDO with cysteine structural analogs and the substrate binding mode with x-ray absorption spectroscopy. In addition to exploring the features required for enzyme inhibition, using substrate derivatives has attracted attention in the development of potent and target-specific drugs (4Lam L.K.P. Arnold L.D. Kalantar T.H. Kelland J.G. Lanebell P.M. Palcic M.M. Pickard M.A. Vederas J.C. J. Biol. Chem. 1988; 263: 11814-11819Abstract Full Text PDF PubMed Google Scholar, 5Kelland J.G. Arnold L.D. Palcic M.M. Pickard M.A. Vederas J.C. J. Biol. Chem. 1986; 261: 3216-3223Abstract Full Text PDF Google Scholar). Because CDO is at a crucial branching point of cysteine catabolism, and several diseases have been linked to this metalloenzyme (6Perry T.L. Norman M.G. Yong V.W. Whiting S. Crichton J.U. Hansen S. Kish S.J. Ann. Neurol. 1985; 18: 482-489Crossref PubMed Scopus (146) Google Scholar, 7Wilkinson L.J. Waring R.H. Toxicol. Vitro. 2002; 16: 481-483Crossref PubMed Scopus (23) Google Scholar, 8Gordon C. Bradley H. Waring R.H. Emery P. Lancet. 1992; 339: 25-26Abstract PubMed Scopus (48) Google Scholar), information about substrate recognition also provides insights for drug design. Many of the cysteine analogs utilized in our current work are metabolites that are present in mammalian cells, and their interaction with CDO could aid in unraveling thiol homeostasis and regulation. Chemicals—Cysteine, cysteine sulfinic acid, and heptafluorobutyric acid were obtained from Aldrich Chemical Co. Sodium phosphate, sodium chloride, and ferrous sulfate were purchased from Fisher Scientific. Yeast extract, Tryptone, phenylmethylsulfonyl fluoride, ampicillin, chloramphenicol, and isopropyl β-d-thiogalactopyranoside were obtained from Sigma. Overexpression, Purification, and Activity Measurement of the Recombinant CDO—BL21(D3)pLysS cells containing the pET-14b/CDO-ORF plasmid were grown in LB media at 22 °C, and the recombinant CDO was purified from the cells by immobilized nickel affinity chromatography as previously reported (9Chai S.C. Jerkins A.A. Banik J.J. Shalev I. Pinkham J.L. Uden P.C. Maroney M.J. J. Biol. Chem. 2005; 280: 9865-9869Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar). Enzyme activity was determined by cysteine sulfinic acid quantitation using the ion-pair reversed-phase high-performance liquid chromatography method as described by Chai et al. (9Chai S.C. Jerkins A.A. Banik J.J. Shalev I. Pinkham J.L. Uden P.C. Maroney M.J. J. Biol. Chem. 2005; 280: 9865-9869Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar). All assays were performed at pH 7.5 in 50 mm phosphate buffer. Gas chromatographic analysis with atomic emission detection was performed on derivatized samples using the procedure reported by Uden et al. (10Uden P.C. Boakye H.T. Kahakachchi C. Hafezi R. Nolibos P. Block E. Johnson S. Tyson J.F. J. Anal. At. Spectrom. 2004; 19: 65-73Crossref Scopus (57) Google Scholar). CDO Treatment with Iodoacetamide—An aliquot (120 μl) of a solution containing 0.22 mg/ml apo- or holo-CDO was treated with 50 μlof 10.2 mm iodoacetamide solution for 4 h at room temperature. The sulfhydryl-specific alkylating reagent iodoacetamide was removed by ultra-filtration followed by incubation of the enzyme with 30 mm cysteine for 4 h at 37 °C. The apo-CDO was reconstituted with ferrous ammonium sulfate prior incubation with the substrate, as previously described (9Chai S.C. Jerkins A.A. Banik J.J. Shalev I. Pinkham J.L. Uden P.C. Maroney M.J. J. Biol. Chem. 2005; 280: 9865-9869Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar). X-ray Absorption Spectroscopy—XAS data for all samples were acquired at beamline X9B at the National Synchrotron Light Source at Brookhaven National Laboratory. CDO samples treated with thrombin to remove the His tag were obtained as previously described (9Chai S.C. Jerkins A.A. Banik J.J. Shalev I. Pinkham J.L. Uden P.C. Maroney M.J. J. Biol. Chem. 2005; 280: 9865-9869Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar). A fraction of the purified enzyme was incubated with 5.3 mm cysteine under anaerobic condition in a Coy chamber, which is approximately the concentration needed to reach Vmax. The samples were contained in polycarbonate holders that were inserted into a slotted aluminum holder and held near 50 K using a helium displex cryostat. The XAS data were collected under dedicated conditions at ∼2.8 GeV and 160–260 mA as previously described (11Bagyinka C. Whitehead J.P. Maroney M.J. J. Am. Chem. Soc. 1993; 115: 3576-3585Crossref Scopus (91) Google Scholar), except that a sagittally focusing Si(111) double-crystal monochromator was used for these studies. The x-ray energy of the focused monochromatic beam was internally calibrated to the first inflection point of iron foil (7112.0 eV). X-ray fluorescence data were collected using a 13-element germanium detector (Canberra) over the range from ∼6.9 to 8.1 KeV, with the vertical primary aperture of 1.0 mm. Harmonic rejection was achieved by use of a nickel focusing mirror left flat. An average of 15 scans for resting CDO and 19 scans for the CDO ES complex was used for EXAFS analysis. The summed, energy-calibrated data files were background-corrected using two third-order polynomial fits and normalized. Single-scattering EXAFS arising from atoms in the first coordination shell of the iron was analyzed using WinXAS (12Ressler T. J. Phys. IV. 1997; 7: 269-270Google Scholar) according to standard procedures (13Davidson G. Clugston S.L. Honek J.F. Maroney M.J. Biochemistry. 2001; 40: 4569-4582Crossref PubMed Scopus (35) Google Scholar). Theoretical phases and amplitudes for EXAFS analyses were obtained from FEFF 8.2 calculations of crystallographic characterized model compounds, (Et4N)2[Fe(p-SC6H4CH3)4] (14Kang B. Cai J. Jiegou Huaxue. 1985; 4: 119-122Google Scholar) and catena-(hexakis(μ-2-imidazoyl-N,N′)bis(imidazole) tri-iron) (15Lehnert R. Seel F. Z. Anorg. Allg. Chem. 1978; 444: 91-96Crossref Scopus (23) Google Scholar). Integer values for the number of scattering atoms in a shell were used in the fits without refinement. This led to the following running parameters for each shell in the first coordination sphere: the distance (r), the disorder parameter (σ2), and phase shift parameter (ΔE0). Models incorporating histidine imidazole ligands were used to fit data due to scattering from atoms in the second and third coordination spheres. These models used imidazole parameters, including multiple scattering pathways contributing >20% intensity that were calculated using FEFF 8.2, as previously described (13Davidson G. Clugston S.L. Honek J.F. Maroney M.J. Biochemistry. 2001; 40: 4569-4582Crossref PubMed Scopus (35) Google Scholar). l-Cysteine is the only known substrate for cysteine dioxygenase (3Ewetz L. Sörbo B. Biochim. Biophys. Acta. 1966; 128: 296-305Crossref PubMed Scopus (59) Google Scholar). Nonetheless, kinetic studies of the inhibition of the enzyme with molecules structurally analogous to the substrate can provide insights into the requirements for substrate binding (Scheme 1). The effect of cysteine analogs on CDO activity was assessed using an in vitro assay that monitors cysteine sulfinic acid formation from cysteine in the presence of varying concentrations of cysteine analogs, where 100% activity is described as CDO activity in the absence of the analogs tested. Our initial characterization of recombinant CDO showed that the enzyme is inhibited by homocysteine but not by methionine (9Chai S.C. Jerkins A.A. Banik J.J. Shalev I. Pinkham J.L. Uden P.C. Maroney M.J. J. Biol. Chem. 2005; 280: 9865-9869Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar). Assays with homocysteine indicated that alkyl chain extension by the addition of an extra methylene in the backbone does not prevent binding to the active site. However, the terminal methyl group attached to the sulfhydryl prevents inhibition by methionine. Studies with S-methylcysteine (data not shown) also show no inhibition, as in the case with methionine. On the other hand, S-carboxymethylcysteine (addition of a terminal carboxylate group) exhibited 50% inhibition at a concentration of 2.3 mm (Fig. 1A). The studies reported above indicated that a charged side chain was required for inhibitor binding and that a sulfhydryl might not be required for inhibition of the enzyme. This was confirmed in studies using aspartic acid, which decreases enzyme activity by half at a concentration of 1.5 mm (Fig. 1B). However, replacing the sulfhydryl by the uncharged hydroxyl group of serine did not affect enzyme activity (data not shown). The inhibition of CDO by aspartate ion suggested that the enzyme might be inhibited by α-ketoglutarate, which is a common cofactor for non-heme iron dioxygenases (16Costas M. Mehn M.P. Jensen M.P. Que L. Chem. Rev. 2004; 104: 939-986Crossref PubMed Scopus (2134) Google Scholar). In fact, α-ketoglutarate was found to inhibit CDO with 50% inhibition at 6.8 mm (Fig. 1C). We also examined the importance of the functional groups at the α-carbon of the amino acid. Mercaptopropionic acid is a cysteine analog lacking the amine group, and at a concentration of 1.2 mm inhibited CDO activity by 50% (Fig. 2A). Cysteamine (2-aminoethanethiol) is synthesized in mammalian tissues from pantetheine (17Novelli G.D. Schmetz F.J. Kaplan N.O. J. Biol. Chem. 1954; 206: 533-545Abstract Full Text PDF PubMed Google Scholar). In contrast to mercaptopropionic acid, it was surprising to discover that cysteamine enhances the activity of recombinant significantly (Fig. 2B). At a reaction time of 45 min, CDO activity increases almost 20 times in the presence of 5.8 mm cysteamine. Cysteamine is not an alternative substrate for the enzyme, because cysteine sulfinic acid can be detected by the assay when similar concentrations of cysteine and cysteamine are present. Furthermore, no oxidation product of cysteamine was detected by the reversed-phase high-performance liquid chromatography method or by gas chromatography analysis with an atomic emission detector. In fact, we did not observe product formation on any of the cysteine analogs tested, including d-cysteine (data not shown). The observation that cysteamine is an activator of CDO but not a substrate suggested a possible redox role. The possibility that an active site sulfhydryl group might be oxidized to a but could be by was an possibility the on the activity of the enzyme with with cysteine S. I. Biochim. Biophys. Acta. PubMed Scopus Google Scholar). However, CDO treated with the iodoacetamide no effect on the enzyme The was obtained by apo-CDO with iodoacetamide of the reagent and with We that there is no essential sulfhydryl group in the active site. CDO is a metalloenzyme that ferrous ion to be active S. I. Biochim. Biophys. Acta. PubMed Scopus Google Scholar). We also the inhibition of recombinant CDO using metal-binding (Fig. and (Fig. also inhibit CDO with a 50% activity at and that these to the active site X-ray absorption spectroscopy was to the interaction of the iron center with cysteine. The data obtained are in and X-ray absorption near analysis that the iron is as The for the K shell of the the is the for the in x-ray that when an at the binding energy of a the to the in x-ray that at the energy where a is at and in the resting and enzyme. The to a has an of in the resting enzyme and 8.1 in the oxidized enzyme, that iron atoms J. Que L. J. Am. Chem. Soc. Scopus Google Scholar). The results of EXAFS analysis of the first coordination show that the of the resting enzyme is of binding substrate, the of the iron site is but is with that cysteine to the iron but is not the Models incorporating histidine imidazole atoms showed that the data are with the presence of two or histidine fits of iron EXAFS data for resting CDO and ES in a The in vitro assays of CDO activity structural analogs of cysteine show that a charged side chain is required for binding at the active site. This negative charge be by a as in the substrate l-cysteine or the or by a as in aspartic acid, and α-ketoglutarate. an uncharged side such as serine or the of cysteine or have no effect on the enzyme is a drug used in the of 1988; Google Scholar). that CDO might be for the of S-carboxymethylcysteine S. S.C. J. 2004; PubMed Scopus Google Scholar), it is to the of this drug on cysteine due to its interaction with for the of an side chain from kinetic studies of CDO in the presence of α-ketoglutarate. are several non-heme iron dioxygenases that use of α-ketoglutarate as an essential cofactor (16Costas M. Mehn M.P. Jensen M.P. Que L. Chem. Rev. 2004; 104: 939-986Crossref PubMed Scopus (2134) Google Scholar, M.J. Chem. Biol. 2002; PubMed Scopus Google Scholar). These are as because of the atoms of is inserted into the substrate, the α-keto acid as the second CDO is not a of this group of because CDO atoms in the substrate J. Biol. Chem. Full Text PDF PubMed Google Scholar). the of our CDO is the first known dioxygenase that has been shown to be inhibited by α-ketoglutarate. This inhibition fits with the other inhibitors in that α-ketoglutarate is an amino acid with a charged side The iron center plays an essential role in we have enzyme by the and (9Chai S.C. Jerkins A.A. Banik J.J. Shalev I. Pinkham J.L. Uden P.C. Maroney M.J. J. Biol. Chem. 2005; 280: 9865-9869Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar). Our current work enzyme by binding of azide or that to possible that for the that the substrate have an side chain is that the side chain is involved in binding to the active site iron The interaction of cysteine with the active site iron was using This from the that the enzyme does not iron be purified from iron-containing and of iron (9Chai S.C. Jerkins A.A. Banik J.J. Shalev I. Pinkham J.L. Uden P.C. Maroney M.J. J. Biol. Chem. 2005; 280: 9865-9869Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar). Nonetheless, information regarding the of the primary coordination of the iron could be obtained from analysis of the XAS arising from the iron that was to the enzyme following of and iron with of the EXAFS arising from the iron center in the resting enzyme are with or to the iron at an average distance of fit the shell of scattering atoms into two at and a in the fit fit in the fit can be obtained by incorporating scattering atoms at and fit the shift in for the distance is to an in the fits led to in or fits with with an number of shell but lacking fits and there is no to in the resting enzyme. The fits obtained from the ES complex are also with a iron center with only or in the primary coordination A shell fit fit an average distance of the shell of scattering atoms into two at and a in the fit fit of of or does not significantly the fit fit The obtained for the ES complex are obtained for the resting enzyme, that the iron site is by substrate binding. The data are with binding of cysteine to the iron center the carboxylate group, but because there is no in coordination number or the data are also with a binding site to the that the However, incorporation of an into any fit to with fits with the number of but lacking there is no to that the cysteine is to the iron the the EXAFS data from the resting enzyme and the ES complex is the intensity of features near 2.3 for phase in the this might the presence of a distance no fits with a were The of cysteine dioxygenase from was obtained with a nickel ion of a non-heme ferrous ion J.G. L.J. E. S. PubMed Scopus Google Scholar). The a nickel center by histidine ligands and Our XAS data from the resting CDO are with ligands and ligands at the data not show a in the near 4 that is of histidine imidazole side the data are not with histidine Models incorporating imidazole show that the features near 2.3 in the ES can be for by histidine ligands fit and incorporation of histidine ligands in the model for the resting enzyme also to a fit of the The intensity of the features arising from the imidazole ligands in the resting enzyme in a of that the intensity the two of data are due to disorder in the resting enzyme iron site fit and We that the iron site in CDO is with the reported for the enzyme. of the substrate derivatives any of product However, the that l-cysteine is the only known substrate that oxidation that a at the active site is required for the to to our d-cysteine was a substrate an the importance of the at the α-carbon for active site binding. possibility is that the and the of the ferrous and are The data are with a model where the cysteine at or near the iron center in a that the near to where the to the ferrous in the EXAFS are with substrate binding to iron a binding could be used to the of cysteine. by aspartate from the of the inhibition by homocysteine from of the due to the side chain (Scheme The and ligands on the resting in were on the from the reported and our current XAS studies. In contrast to the other cysteine structural analogs, cysteamine was shown to the enzyme activity but was not a substrate. cysteamine CDO is not a redox role is possible redox role be to or an active site cysteine sulfhydryl This possibility is not with the that CDO activity is by Recombinant CDO was treated with a reagent used in a prior of that are for enzyme J.F. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). holo-CDO with iodoacetamide followed by its by enzyme activity was The results are of apo-CDO with iodoacetamide followed by reagent and with ferrous is that cysteine a role in et al. S. S.C. J. 2004; PubMed Scopus Google Scholar) reported that CDO is inhibited by to the assay In our we that of the cysteine by could to the of an enzyme activity The role of cysteamine in the activity of CDO is in several Cysteamine to a role in cysteine homeostasis at the and are for the intracellular and the of the the by for or C. S. J. PubMed Google Scholar). is an disorder by a of of the due to in the C. 2002; PubMed Scopus (35) Google Scholar, S. C. B. J. 2001; PubMed Scopus Google Scholar). of the results in formation that in to that and formation in the S. C. G. M. M. M. C. Biol. 2002; PubMed Scopus Google Scholar). Cysteamine has been used to from because it concentrations and the with the B. J. M. J. PubMed Scopus Google Scholar). is to be removed from the as but of in the is M. J. PubMed Google Scholar). being from the to the be removed by of the cells or to other metabolites by CDO activity at the cysteamine to a role in the regulation of CDO of CDO concentration was in with a high or amino but no in CDO was detected J. Google Scholar). Studies with rat indicated a similar cysteine in and CDO concentration M.P. C.L. Am. J. 2004; PubMed Scopus Google Scholar). was suggested that CDO is not at the but by its In a CDO is and for by the M.P. C.L. Am. J. 2004; PubMed Scopus Google Scholar). cysteine analogs or molecules to CDO cysteamine was shown to be as as cysteine in CDO The for CDO by the is not but it was that upon cysteine or cysteamine binding could with cysteamine might a role in CDO it also its activity for cysteine We the of The Chemical for of this
24
Esteban C. Dell’Angelica, Chris Mullins, Steve Caplan et al. · The FASEB Journal · 2000 · 474 citations
Structure and mechanism of mouse cysteine dioxygenase
Jason G. McCoy, L.J. Bailey, E. Bitto et al. · Proceedings of the National Academy of Sciences · 2006 · 208 citations · Full text